Actualités et Activités de Hanmi
Présence
Hanmi est une société cotée sous le symbole boursier HANPF (KR).
Dirigeants
Voir l'organigramme avec ses 6 principaux dirigeants
Biographies les plus recherchées chez Hanmi
- Jong-Soo Woo, Co-Chief Executive Officer
- Sung-Ki Lim, Chairman of the Board
- Gwan-Sun Lee, Chairman of the Board
Créer une alerte
pour suivre les mouvements de dirigeants chez Hanmi.
Pharmacie
Hanmi a 1 834 concurrents dont Pfizer (Etats—Unis), Sanofi (France) et Eli Lilly (Etats—Unis).
Actualités en fusion/acquisition en Pharmacie.
- Imbria Pharmaceuticals vient d'annoncer une levée de fonds de 58 millions de dollars. (publié le 10 avril 2025).
- Clario a acquis NRx Pharmaceuticals (publié le 18 mars 2025).
- Knight Therapeutics has announced the acquisition of Paladin Labs (publié le 12 mars 2025).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par Hanmi
- Hanmi Pharmaceutical's Groundbreaking Drug for Congenital Hyperinsulinism, 'Efpegerglucagon' Advances in Global Phase 2 Clinical Trial | Hanmi Pharmaceutical
- 'Efocipegtrutide' by Hanmi Pharmaceutical Shows Promising Efficacy in Liver Fibrosis Improvement | Hanmi Pharmaceutical
- Hanmi Pharmaceutical and Beijing Hanmi Progress Clinical Trials of Co-developed BH3120 as a Next-Generation Cancer Immunotherapy | Hanmi Pharmaceutical
- Hanmi Unveils its Next-Generation ‘MAT2A Inhibitor’ Targeting Metabolic Vulnerabilities of Cancer Cells | Hanmi Pharmaceutical
- Hanmi Pharmaceutical Partners with Tabuk Pharmaceuticals through an Exclusive License and Supply Agreement for Innovative Value-Added Medicines in the MENA Region | Hanmi Pharmaceutical
- Hanmi Unveils Its Dual Action ‘EZH1/2’ Inhibitor Targeting Epignetic Regulation | Hanmi Pharmaceutical
- Hanmi Pharmaceutical and GC Biopharma Receives IND Clearance for Phase 1/2 Clinical Trial from the US FDA | Hanmi Pharmaceutical
- FDA Approves Hanmi's Innovative, Next-Generation Immunomodulatory Anticancer Drug for Phase 1 Clinical Trial | Hanmi Pharmaceutical
- Recent Data for Hanmi’s 'Novel Long-Acting GLP-1/GIP/GCG Triple Agonist' Support Potential for ‘Best-In-Class’ Weight Loss Effect in Treating Obesity | Hanmi Pharmaceutical
- Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in Combination with KEYTRUDA® (pembrolizumab) | Hanmi Pharmaceutical
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Hanmi
- Hanmi sur Wikipédia, Google News & Yahoo Finance en 1-click
- Hanmi sur LinkedIn, Twitter & YouTube en 1-click
